Methotrexate for the treatment of cutaneous dermatomyositis

Journal of the American Academy of Dermatology

Volumn 68, Issue 6, 2013, Pages 1043-1045

  Click, James W ^a   Qureshi, Abrar A ^b   Vleugels, Ruth Ann ^b  

^a Harvard Combined Dermatology Residency Program   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYCHLOROQUINE; METHOTREXATE; PREDNISONE;

ALOPECIA; CORTICOSTEROID THERAPY; DERMATOLOGIST; DERMATOMYOSITIS; DRUG CLEARANCE; DRUG WITHDRAWAL; ELECTRONIC MEDICAL RECORD; HUMAN; HYPERTRANSAMINASEMIA; LETTER; LEUKOPENIA; PANNICULITIS; PRIORITY JOURNAL; SKIN DISEASE; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 84877822949     PISSN: 01909622     EISSN: 10976787     Source Type: Journal    
DOI: 10.1016/j.jaad.2013.01.008     Document Type: Article

References (5)

1. J.P. Callen Dermatomyositis Lancet 355 2000 53 57
2. M.E. Zieglschmid-Adams, A.G. Pandya, and S.B. Cohen Treatment of dermatomyositis with methotrexate J Am Acad Dermatol 32 1995 754 757
3. J.S. Kasteler, and J.P. Callen Low-dose methotrexate administered weekly is an effective corticosteroid-sparing agent for the treatment of the cutaneous manifestations of dermatomyositis J Am Acad Dermatol 36 1997 67 71
4. N.M. Anand, M. Amira, and R. Schwartz Treatment of dermatomyositis with methotrexate Lancet 292 1968 485 488
5. R.Q. Klein, C.A. Bangert, M. Costner, M.K. Connolly, A. Tanikawa, and J. Okawa Comparison of the reliability and validity of outcome instruments for cutaneous dermatomyositis Br J Dermatol 159 2008 887 894